Anestezi Sırasında Gelişen Malign Hipertermi ve Yönetimi
Synopsis
Malignant hyperthermia (MH) is an autosomal dominant genetic disorder of skeletal muscle triggered by exposure to volatile anesthetics such as desflurane, isoflurane, sevoflurane, and halothane, or the depolarizing muscle relaxant succinylcholine. Uncontrolled sarcoplasmic calcium release, most commonly caused by RYR1 gene mutations, leads to sustained muscle contraction, excessive oxygen and ATP consumption, and increased carbon dioxide production. The earliest clinical signs of MH are an unexplained increase in EtCO₂, sinus tachycardia, and muscle rigidity, followed by rapidly rising hyperthermia, mixed metabolic and respiratory acidosis, hyperkalemia, and rhabdomyolysis. Management requires the immediate discontinuation of triggering anesthetics, hyperventilation with 100% high-flow oxygen, aggressive body cooling, and prompt administration of dantrolene sodium (initial dose of 2.5 mg/kg IV), which is the only specific antidote. Widespread use of dantrolene, capnography, and core temperature monitoring has significantly reduced MH mortality from 70–80% to under 5%. Postoperatively, patients must be monitored in an intensive care unit for at least 24 hours to watch for recrudescence and complications such as DIC, renal impairment, or cardiac arrest.
References
Mullins MF. Malignant Hyperthermia: A Review. Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses. 2018;33(5):582-589.
Litman RS, Smith VI, Larach MG, et al. Consensus Statement of the Malignant Hyperthermia Association of the United States on Unresolved Clinical Questions Concerning the Management of Patients With Malignant Hyperthermia. Anesthesia and analgesia. 2019;128(4):652-659.
Rosenberg H, Davis M, James D, et al. Malignant hyperthermia. Orphanet journal of rare diseases. 2007;2:21.
Brady JE, Sun LS, Rosenberg H, et al. Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005. Anesthesia and analgesia. 2009;109(4):1162-1166.
Larach MG, Gronert GA, Allen GC, et al. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesthesia and analgesia. 2010;110(2):498-507.
Ibarra Moreno CA, Hu S, Kraeva N, et al. An Assessment of Penetrance and Clinical Expression of Malignant Hyperthermia in Individuals Carrying Diagnostic Ryanodine Receptor 1 Gene Mutations. Anesthesiology. 2019;131(5):983-991.
Kim DC. Malignant hyperthermia. Korean journal of anesthesiology. 2012;63(5):391-401.
Biesecker LG, Dirksen RT, Girard T, et al. Genomic Screening for Malignant Hyperthermia Susceptibility. Anesthesiology. 2020;133(6):1277-1282.
Stamm DS, Aylsworth AS, Stajich JM, et al. Native American myopathy: congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia. American journal of medical genetics Part A. 2008;146a(14):1832-1841.
Carpenter D, Ringrose C, Leo V, et al. The role of CACNA1S in predisposition to malignant hyperthermia. BMC medical genetics. 2009;10:104.
Litman RS, Griggs SM, Dowling JJ, et al. Malignant Hyperthermia Susceptibility and Related Diseases. Anesthesiology. 2018;128(1):159-167.
Gronert GA, Theye RA. Halothane-induced porcine malignant hyperthermia: metabolic and hemodynamic changes. Anesthesiology. 1976;44(1):36-43.
Louis CF, Zualkernan K, Roghair T, et al. The effects of volatile anesthetics on calcium regulation by malignant hyperthermia-susceptible sarcoplasmic reticulum. Anesthesiology. 1992;77(1):114-125.
Vladutiu GD, Isackson PJ, Kaufman K, et al. Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. Molecular genetics and metabolism. 2011;104(1-2):167-173.
Gurnaney H, Brown A, Litman RS. Malignant hyperthermia and muscular dystrophies. Anesthesia and analgesia. 2009;109(4):1043-1048.
Bojanić K, Kivela JE, Gurrieri C, et al. Perioperative course and intraoperative temperatures in patients with osteogenesis imperfecta. European journal of anaesthesiology. 2011;28(5):370-375.
MHAUS. Does Noonan Syndrome Increase Malignant Hyperthermia Susceptibility? [Available from: https://www.mhaus.org/healthcare-professionals/mhaus-recommendations/does-noonan-syndrome-increase-malignant-hyperthermia-susceptibility/ (Accessed 25th July 2021).
Baines DB, Douglas ID, Overton JH. Anaesthesia for patients with arthrogryposis multiplex congenita: what is the risk of malignant hyperthermia? Anaesthesia and intensive care. 1986;14(4):370-372.
Bello N, Adnet P, Saulnier F, et al. [Lack of sensitivity to per-anesthetic malignant hyperthermia in 32 patients who developed neuroleptic malignant syndrome]. Annales francaises d'anesthesie et de reanimation. 1994;13(5):663-668.
Strazis KP, Fox AW. Malignant hyperthermia: a review of published cases. Anesthesia and analgesia. 1993;77(2):297-304.
Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80(4):771-779.
Rosenberg H, Sambuughin N, Riazi S. Malignant Hyperthermia Susceptibility. 2003 Dec 19 [Updated 2020 Jan 16]. Seattle (WA): University of Washington, Seattle: GeneReviews. 1993-2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1146/.
Robinson RL, Anetseder MJ, Brancadoro V, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? European journal of human genetics : EJHG. 2003;11(4):342-348.
Gonsalves SG, Dirksen RT, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes. Clinical pharmacology and therapeutics. 2019;105(6):1338-1344.
Kim TW, Nemergut ME. Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and present practice. Anesthesiology. 2011;114(1):205-212.
MHAUS. Preparing the Anesthesia Machine for MHS Patients [Available from: https://www.mhaus.org/healthcare-professionals/be-prepared/preparing-the-anesthesia-machine/ (Accessed 25th July 2021).
Glahn KPE, Bendixen D, Girard T, et al. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines. Br J Anaesth. 2020;125(2):133-140.
Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. Jama. 2005;293(23):2918-2924.
Glahn KPE, Ellis FR, Halsall PJ, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. British Journal of Anaesthesia. 2010;105(4):417-420.
MHAUS. Emergency Treatment for An Acute MH Event [Available from: https://www.mhaus.org/healthcare-professionals/managing-a-crisis/ (Accessed 25th July 2021).
Brandom BW, Larach MG, Chen MS, et al. Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Anesthesia and analgesia. 2011;112(5):1115-1123.
MHAUS. Post Acute Phase [Available from: https://www.mhaus.org/healthcare-professionals/after-a-crisis/post-acute-phase/ (Accessed 25th July 2021).
Rosero EB, Adesanya AO, Timaran CH, et al. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology. 2009;110(1):89-94.
Larach MG, Brandom BW, Allen GC, et al. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesthesia and analgesia. 2014;119(6):1359-1366.